The Bruton's tyrosine kinase inhibitor tolebrutinib is reportedly the first agent to show benefit in patients with nonrelapsing secondary progressive MS.
Liver enzyme elevations were observed in 4.1% of participants receiving tolebrutinib compared with 1.6% in the placebo group. Friday, Sanofi SA SNY released data from the HERCULES phase 3 study of ...
Some results have been hidden because they may be inaccessible to you